# Research timeline and gaps: Menopause Hormones: Symptoms, Prevention and Testosterone

Selected publication milestones, not an exhaustive history or discovery priority claim.

**1985 — Transdermal estradiol dose experiments linked measured exposure to symptom suppression in a controlled short trial.** [Original PMID3928674](https://pubmed.ncbi.nlm.nih.gov/3928674/).

**1998 — PEPI compared systemic regimens and showed vasomotor relief without a matching generalized cognitive/affective benefit.** [Original PMID9840563](https://pubmed.ncbi.nlm.nih.gov/9840563/).

**2002 — A randomized laboratory experiment tested the predicted sweating-threshold response using physiological symptom recording.** [Original PMID11872200](https://pubmed.ncbi.nlm.nih.gov/11872200/).

**2002 — WHI combined-regimen prevention outcomes forced separation of symptom relief from chronic disease benefit and harm.** [Original PMID12117397](https://pubmed.ncbi.nlm.nih.gov/12117397/).

**2003 — WHIMS tested incident dementia in an older enrolled population rather than assuming symptom efficacy conferred brain protection.** [Original PMID12771112](https://pubmed.ncbi.nlm.nih.gov/12771112/).

**2008 — APHRODITE established an indication-specific testosterone counterexample: modest HSDD benefit without concomitant estrogen.** [Original PMID18987368](https://pubmed.ncbi.nlm.nih.gov/18987368/).

**2014 — MsFLASH directly compared estradiol, venlafaxine and placebo for baseline bothersome vasomotor symptoms.** [Original PMID24861828](https://pubmed.ncbi.nlm.nih.gov/24861828/).

**2014 — A selective verbal-learning testosterone signal remained bounded by null cognitive domains and general wellbeing.** [Original PMID24716847](https://pubmed.ncbi.nlm.nih.gov/24716847/).

**2016 — ELITE showed why early-start surrogate vascular changes and hard disease prevention must be distinguished.** [Original PMID27028912](https://pubmed.ncbi.nlm.nih.gov/27028912/).

**2018 — REPLENISH evaluated a defined oral estradiol/progesterone capsule with symptom and finite endometrial endpoints.** [Original PMID29889748](https://pubmed.ncbi.nlm.nih.gov/29889748/).

**2024 — A tested fezolinetant regimen failed to outperform placebo in MOONLIGHTI, mapping a nonhormonal context limit.** [Original PMID38818888](https://pubmed.ncbi.nlm.nih.gov/38818888/).

**2025 — OASIS3 expanded contemporary neurokinin-pathway symptom evidence while separating confirmatory and descriptive follow-up endpoints.** [Original PMID40920404](https://pubmed.ncbi.nlm.nih.gov/40920404/).

## Research gaps

The complete endocrine-to-thermoregulatory mediator sequence is not isolated by ordinary efficacy trials.

Allocation-guess assessment and objective symptom sensing are incompletely integrated in large hormone trials.

Long-term hard endpoints for contemporary transdermal estradiol/micronized progesterone begun near menopause need direct assessment rather than extrapolation from oral CEE/MPA or observational continuation.

Physiological-dose testosterone requires replicated patient-important nonspecific cognition, fatigue and muscle-function endpoints; supraphysiologic dose signals do not establish ordinary replacement benefit.

Rare breast, vascular and liver harms require formulation-specific long-term surveillance and cannot be excluded by small short trials.

## Boundary experiment

Run a prospectively registered, adequately powered symptomatic-menopause trial of a measured systemic estradiol regimen, placebo and a mechanistically distinct nonhormonal comparator, with identical contact, allocation-guess checks, objective thermal/skin-conductance sensing and daily patient-important symptoms. Embed baseline-defined age/stage and route strata and a blinded randomized-withdrawal phase; test the hypothesized mediator without conditioning on response. A separate long-horizon contemporary-regimen prevention trial is required for SC3.